CK Life Sciences' (HKG:0775) laboratory tests for novel cancer vaccines have shown "promising" early results, according to a Friday filing with the Hong Kong bourse.
The vaccines target Trophoblast Cell Surface Antigen 2, which helps in cell multiplication, migration, and invasion in breast, lung, pancreatic, and colorectal cancers, among others, the filing said.